Thus, we engineered a BiTE construct using the GPC-1 binding sequence of Miltuximab® and demonstrated effective and specific T cell activation and PCa cell lysis in two phenotypically distinct GPC-1high PCa cell lines, namely DU-145 and PC3 (derived from a PCa brain metastasis, and bone metastasis, respectively). The gene discussed is GPC1; the disease is posterior cortical atrophy.